Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1846 related articles for article (PubMed ID: 34888843)

  • 1. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.
    Jarboe T; Tuli NY; Chakraborty S; Maniyar RR; DeSouza N; Xiu-Min Li ; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():1-31. PubMed ID: 34888842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BTLA-HVEM complex - The future of cancer immunotherapy.
    Wojciechowicz K; Spodzieja M; Wardowska A
    Eur J Med Chem; 2024 Mar; 268():116231. PubMed ID: 38387336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
    Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
    Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.
    Maniyar RR; Chakraborty S; Jarboe T; Suriano R; Wallack M; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():123-143. PubMed ID: 34888847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
    Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
    Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
    Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.
    Sordo-Bahamonde C; Lorenzo-Herrero S; Granda-Díaz R; Martínez-Pérez A; Aguilar-García C; Rodrigo JP; García-Pedrero JM; Gonzalez S
    Mol Cancer; 2023 Aug; 22(1):142. PubMed ID: 37649037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 13. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
    Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
    J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
    Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
    [No Abstract]   [Full Text] [Related]  

  • 15. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
    Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for anaplastic thyroid carcinoma: the present and future.
    Lu X; Bao L; Pan Z; Ge M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):675-684. PubMed ID: 35347912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
    Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
    J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
    Passaro C; Borriello F; Vastolo V; Di Somma S; Scamardella E; Gigantino V; Franco R; Marone G; Portella G
    Oncotarget; 2016 Jan; 7(2):1500-15. PubMed ID: 26625205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BTLA inhibition has a dominant role in the
    Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
    Front Immunol; 2022; 13():956694. PubMed ID: 36081508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.
    Kuncewicz K; Battin C; Sieradzan A; Karczyńska A; Orlikowska M; Wardowska A; Pikuła M; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.